Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • It is safe to...

    It is safe to supervise medical termination of pregnancy via telemedicine, finds study

    Written by Hina Zahid Published On 2019-08-16T19:15:22+05:30  |  Updated On 16 Aug 2019 7:15 PM IST
    It is safe to supervise medical termination of pregnancy via telemedicine, finds study
    It is safe to supervise medical abortions via telemedicine, finds study.Telemedicine may be employed as a strategy for expanding patients’ access to safe, legal abortion, including for those living in remote or rural areas.

    Medical termination of a pregnancy with medication under virtual supervision from a clinician is just as effective and safe as doing so at a medical facility, a study across four U.S states suggests. The findings mean that telemedicine could give more U.S. patients access to safe and legal abortion, especially in states passing legislation to impose severe restrictions on a woman’s ability to terminate her pregnancy, the researchers said.


    “Telemedicine can improve health equity by ensuring that more people have access to the care they need - including abortion - in a timely manner,” said study leader Julia Kohn, national director of research, evaluation and data analytics at the Planned Parenthood Federation of America.


    “As the access to abortion shrinks across the country, telemedicine is one strategy for expanding patients’ access to safe, legal abortion, including for those living in remote or rural areas,” Kohn told Reuters Health by email.


    Access to abortion, which includes medication abortion and surgical procedures, has shrunk in the U.S., with 90% of all counties lacking an abortion provider as of 2014, the study team notes in Obstetrics & Gynecology. In addition, 27 U.S. cities with populations over 100,000 have no abortion provider within 100 miles.


    In a medication abortion, two drugs that come in pill form, mifepristone and misoprostol, are given to terminate an early pregnancy.


    Mifepristone, which is taken a couple of days before misoprostol, is only available in hospitals and clinics under the supervision of a certified provider, under U.S. Food and Drug Administration regulations.


    Traditionally, patients seeking a medication abortion at Planned Parenthood, the largest single provider of abortions in the U.S., visit a health center and receive in-person care from staff. After giving consent, they meet with their abortion provider, who is usually a clinician, such as a doctor or a nurse practitioner, and take the mifepristone dose in the clinician’s presence. Sometimes, when a clinician is not available on-site, patients at the health center meet with the doctor or nurse through a video-conferencing platform and take the mifepristone in view of the clinician.


    For the study, researchers looked at data from 26 Planned Parenthood centers across Alaska, Idaho, Nevada and Washington on medication abortions provided from April 2017 to March 2018.


    Of more than 5,900 patients who underwent medication abortion, 738 women “met” with providers who were not physically at the clinic.


    Among the patients who took the first pill after an in-person meeting with a clinician, 77% followed up with the clinic within 45 days to report the results, while 60.3% of telemedicine patients followed up.


    Of the women who followed up, 73 had ongoing pregnancies. This included 0.5% of the telemedicine group and 1.8% of the in-person group. Among 188 women who required an aspiration abortion - either for ongoing pregnancy or incomplete abortions - just six were telemedicine patients.


    The study team also looked at serious side effects or safety issues, like heavy bleeding, and found 17 that were related to the abortions; one of these occurred in a telemedicine patient. This rate of adverse events is low and aligns with published literature, the researchers note.


    It’s unclear why rates of ongoing pregnancy and aspiration abortions were higher in the women who met with clinicians in person, but it’s possible the difference is due to the lower rate of follow-up reporting from the telemedicine group, the authors note. The fact that about one-quarter of all patients did not follow up is one limitation of the study, they point out.


    Still, the study team writes, the results show across diverse states that telemedicine supervision of women when they take mifepristone can be as safe and effective as the standard procedure of administering the medication face-to-face with a clinician in a medical setting.


    “To the extent that state bans on telemedicine for abortion rest on arguments of improved patient safety, the findings of this and previous studies do not support such contentions,” the study team concludes.

    heavy bleedingJulia Kohnlegal abortionMedical abortionsMedical Facilitymedical termination of pregnancymifepristonemisoprostolObstetrics & GynecologyPregnancytelemedicineU.S. Food and Drug Administration
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Hina Zahid
    Hina Zahid
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok